X

Trial Profile

A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients with Atypical Hemolytic Uremic Syndrome

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 17 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemdisiran (Primary)
Indications Atypical Haemolytic Uraemic Syndrome
Focus Proof of concept; Therapeutic Use
Sponsors Alnylam Pharmaceuticals

Most Recent Events

03 Oct 2018 This trial was Completed in Sweden (end date: 2018-09-12), according to European Clinical Trials Database.
25 Sep 2018 Status changed from recruiting to discontinued.
02 Aug 2018 According to an Alnylam Pharmaceuticals media release, initial data from this trial is expected in 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com